These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30634054)

  • 1. A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections.
    Xiao T; Wu Z; Shi Q; Zhang X; Zhou Y; Yu X; Xiao Y
    J Glob Antimicrob Resist; 2019 Jun; 17():147-156. PubMed ID: 30634054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing
    Xiao T; Yang K; Zhou Y; Zhang S; Ji J; Ying C; Shen P; Xiao Y
    Antimicrob Resist Infect Control; 2019; 8():144. PubMed ID: 31467670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
    Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
    Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
    Haruki Y; Hagiya H; Haruki M; Sugiyama T
    J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.
    Tumbarello M; Sali M; Trecarichi EM; Leone F; Rossi M; Fiori B; De Pascale G; D'Inzeo T; Sanguinetti M; Fadda G; Cauda R; Spanu T
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3244-52. PubMed ID: 18591273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology, Risk Factors, and Clinical Outcomes of Bloodstream Infection due to Extended-Spectrum Beta-Lactamase-Producing
    Liang T; Xu C; Cheng Q; Tang Y; Zeng H; Li X
    Microb Drug Resist; 2021 Jun; 27(6):800-808. PubMed ID: 33232654
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk factors for antibiotic resistance and mortality in patients with bloodstream infection of Escherichia coli.
    Zhao S; Wu Y; Dai Z; Chen Y; Zhou X; Zhao J
    Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):713-721. PubMed ID: 35190911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae.
    Scheuerman O; Schechner V; Carmeli Y; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Molina J; Hernández-Torres A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Navarro-San Francisco C; Bonomo RA; Paterson DL; Pascual A; Rodríguez-Baño J;
    Infect Control Hosp Epidemiol; 2018 Jun; 39(6):660-667. PubMed ID: 29618394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for and mortality of extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections.
    Superti SV; Augusti G; Zavascki AP
    Rev Inst Med Trop Sao Paulo; 2009; 51(4):211-6. PubMed ID: 19739001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 131.
    Cho SY; Kang CI; Cha MK; Wi YM; Ha YE; Chung DR; Lee NY; Peck KR; Song JH;
    Microb Drug Resist; 2015 Aug; 21(4):463-9. PubMed ID: 25756854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Wu UI; Yang CS; Chen WC; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2010 Aug; 43(4):310-6. PubMed ID: 20688291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
    Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
    Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
    Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; de Cueto M; Ríos MJ; Hernández JR; Pascual A
    Clin Infect Dis; 2006 Dec; 43(11):1407-14. PubMed ID: 17083012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.
    Van Aken S; Lund N; Ahl J; Odenholt I; Tham J
    Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy.
    Nasir N; Ahmed S; Razi S; Awan S; Mahmood SF
    BMC Res Notes; 2019 Sep; 12(1):611. PubMed ID: 31547853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.